Get the Stockscreener App
45.03
0.35%
-0.16
After Hours:
45.09
0.06
+0.13%
Veracyte Inc stock is traded at $45.03, with a volume of 1.40M.
It is down -0.35% in the last 24 hours and up +33.58% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$45.19
Open:
$45.46
24h Volume:
1.40M
Relative Volume:
1.44
Market Cap:
$3.59B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
41.46
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+17.02%
1M Performance:
+33.58%
6M Performance:
+2.32%
1Y Performance:
+64.34%
1-Day Range:
$44.81
$46.00
1-Week Range:
$39.05
$46.00
52-Week Range:
$22.61
$50.71
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
45.03 | 3.61B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Here's why Veracyte (VCYT) is a strong momentum stock - MSN
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally? - TradingView
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - Yahoo Finance UK
Assessing Veracyte (VCYT) Valuation After Phase III Success For Prosigna And Decipher Cancer Tests - Yahoo Finance
Veracyte director Robert S Epstein sells $440,129 in company stock - Investing.com India
Insider Sell: Robert Epstein Sells 10,000 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte director Robert S Epstein sells $440,129 in company stock By Investing.com - Investing.com Australia
Veracyte Insider Sold Shares Worth $440,129, According to a Recent SEC Filing - Moomoo
Veracyte (VCYT) director sells 10,000-share block under 10b5-1 plan - Stock Titan
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings - Business Wire
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer - Business Wire
Kevin Haas Named Chief Development and Technology Officer at Veracyte - Medical Product Outsourcing
Veracyte Jumps 7.8% Amid Sector-Wide Rally - AlphaStreet
[144] VERACYTE, INC. SEC Filing - Stock Titan
Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test - Sahm
Veracyte to Participate in Upcoming June 2026 Investor Conferences - BioSpace
Veracyte to Participate in Upcoming Investor Conferences - 01net
Veracyte stock (US92347M1009): diagnostics specialist back in the spotlight after new data and index - AD HOC NEWS
CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Maintains Target Price $42 - Moomoo
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer - marketscreener.com
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term - Yahoo Finance
A Look At Veracyte (VCYT) Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test - Sahm
Veracyte stock (US92347M1009): earnings momentum and cancer diagnostics focus - AD HOC NEWS
Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test - Moomoo
Veracyte (VCYT) Gains CMS Coverage for TrueMRD Monitoring Test - GuruFocus
Veracyte Gains Medicare Coverage for Muscle-Invasive Bladder Cancer Recurrence Monitoring Test - Contract Pharma
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS - TipRanks
Veracyte’s bladder cancer test receives Medicare coverage By Investing.com - Investing.com South Africa
Veracyte’s bladder cancer test receives Medicare coverage - Investing.com
Veracyte secures Medicare coverage for Truemrd monitoring test in muscle-invasive bladder cancer - marketscreener.com
Veracyte Secures Medicare Coverage For Truemrd Monitoring Test In Muscle-Invasive Bladder Cancer - TradingView
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings - simplywall.st
Statutory Profit Doesn't Reflect How Good Veracyte's (NASDAQ:VCYT) Earnings Are - Yahoo Finance
Veracyte Inc (VCYT) Shares Fall 3.3% -- What GF Score of 82 Tells Investors - GuruFocus
Artisan Partners (NYSE: VCYT) reports 5.50M shares, 6.9% stake in Veracyte - Stock Titan
Morgan Stanley Initiates Veracyte(VCYT.US) With Sell Rating, Announces Target Price $39.7 - Moomoo
State Street (VCYT) discloses 5.04M-share, 6.3% holding in Veracyte - Stock Titan
State of New Jersey Common Pension Fund D Invests $1.13 Million in Veracyte, Inc. $VCYT - MarketBeat
Veracyte | 4: Statement of changes in beneficial ownership of securities-Officer Stapley Marc - Moomoo
Why Veracyte Stock Is Skyrocketing Higher This Week - AOL.com
Veracyte (VCYT) Is Up 23.8% After Raising 2026 Guidance And Expanding Decipher Cancer Studies - simplywall.st
Veracyte (VCYT) Q1 2026 Earnings: Revenue Up 21%, EPS Quadruples, Shares Climb 23%News and Statistics - IndexBox
Veracyte, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VCYT) 2026-05-08 - Seeking Alpha
Insider Sell: Annie Mcguire Sells 10,204 Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte SVP McGuire sells $398,211 in shares By Investing.com - Investing.com South Africa
Veracyte SVP McGuire sells $398,211 in shares - Investing.com
Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan - Stock Titan
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):